Announcement on the Transfer of Holding Subsidiary Equity
Filed with SSE · · 5 pages · Chinese
Shandong Buchang Pharmaceuticals Co., Ltd. on 6ix
Earlier from Shandong Buchang Pharmaceuticals
- Announcement on Participation in the Auction for the Qualification as a Restructuring Investor and Its Results
- Announcement on Partial Drugs of the Subsidiary Being Selected for National Procurement Continuation After the Expiry of Agreement
- Announcement on Pledge Release and Re-pledge of Partial Shares Held by Controlling Shareholder
- Announcement on Resolutions of the 43rd Meeting of the 5th Board of Directors
- Announcement on Progress in Proposed Waiver of Preemptive Rights for Equity of Holding Subsidiary and Related Party Transactions
Later from Shandong Buchang Pharmaceuticals
- Announcement on Resolutions of the 46th Meeting of the 5th Board of Directors
- Announcement on Obtaining Malaysian Drug Registration Certificate for Yangzhengheji Decoction
- Announcement on 2025 Final Profit Distribution and Requesting the General Meeting of Shareholders to Authorize the Board of Directors to Prepare the 2026 Interim Dividend Plan
- Announcement on Change of Drug Production License of the Company and Wholly-owned Subsidiary
- Announcement on Receipt by its Holding Subsidiary of the Notice of Grant for the 2026 Project under the National Science and Technology Major Project for Prevention and Control of Emerging, Re-emerging and Major Infectious Diseases
Follow Shandong Buchang Pharmaceuticals into a list and get an email when it puts out news.
Follow Shandong Buchang Pharmaceuticals